Tolerising antigen-specific immunotherapy for type 1 diabetes

1 型糖尿病的耐受性抗原特异性免疫疗法

• 批准号: nhmrc : 2002917
• 金额: $ 139.55万
• 依托单位国家: 澳大利亚
• 项目类别: Ideas Grants
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/tolerising-antigen-specific-1-diabetes/1780029
• 关键词: Tolerising; antigen; specific; immunotherapy; type

We have developed a new immunotherapy to treat the underlying causes of type 1 diabetes (T1D) while leaving the rest of the immune system intact. To use this in patients, we need better tests to know when immune therapy is working. We will develop new methods to design the therapy and tools to track the relevant immune cells in T1D that work in variable patient groups. The knowledge gained will speed the pace of development and increase the chance of success of immunotherapy in T1D.

我们已经开发出一种新的免疫疗法来治疗1型糖尿病（T1D）的潜在原因，同时保持免疫系统的其余部分完好无损。为了在病人身上使用这种方法，我们需要更好的测试来知道免疫疗法何时起作用。我们将开发新的方法来设计治疗和工具来跟踪T1D中在不同患者群体中起作用的相关免疫细胞。所获得的知识将加快发展的步伐，增加T1D免疫治疗成功的机会。